Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM.
Here’s what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics missed estimated earnings by 128.57%, reporting an EPS of $-0.04 versus an estimate of $0.14.
Revenue was down $85.00 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.04 which was followed by a 4.19% increase in the share price the next day.
Here’s a look at Adaptimmune Therapeutics’s past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.26 | -0.24 | -0.25 | -0.23 |
| EPS Actual | -0.30 | -0.24 | -0.24 | -0.24 |
| Revenue Estimate | 1.37M | 1.36M | 1.83M | 1.98M |
| Revenue Actual | 1.20M | 3.10M | 434.00K | 1.50M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
